The ability of bispecific antibodies and antibody drug conjugates to interact with two biologic binding sites at once creates major leverage for interfering with a disease mechanism intercellularly as well as heightened risks for predicting clinical results and for achieving manufacturing deadlines.  This session will examine the successes of the first generation of nearly a dozen approved immuno-oncology bispecifics and explore lessons from the more than 180 such programs in development worldwide, plus explore non-oncology opportunities for inflammatory diseases and more.